MBRX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Moleculin Biotech Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 2.12 USD
1.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -25.5% below the Trend Line and sits at 1.9% of its 52-week range. The latest completed week returned 1.0%, after a -35.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 15 out of 100
Latest Close 2.12 USD 24 Jul 2026
1W Return 1.0% latest completed week
4W Return -35.2% short-term follow-through
12W Return -15.5% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.1x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 43.81% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.0% Latest completed week; four-week move -35.2%. Indicator stack 0/63 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.81% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 55/100 56 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -25.5% below the Trend Line and sits at 1.9% of its 52-week range. The latest completed week returned 1.0%, after a -35.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.1x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2012-week average 0.12

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -35.2% over four weeks, -15.5% over 12 weeks, and -85.0% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.0%
4W-35.2%
12W-15.5%
26W-54.7%
52W-85.0%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.90Latest activity-pressure read.
Pressure change-38.0%Four-week change in activity pressure.
Leadership-69.67Latest relative-leadership reading.
RS change-13.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality48/100Profitability and accounting quality. Underlying universe rank 53; rank 1 is best.
Momentum50/100Medium-term price momentum. Underlying universe rank 51; rank 1 is best.
Growth50/100Revenue and earnings growth. Underlying universe rank 51; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-486.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-438.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.7%
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
0.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity6 / 12

6 acquisitions and 12 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 56 relevant articles.

16 positive · 36 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-88.7%Distance below the 52-week high.
13-week volatility11.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+18.4%Week of 27 Mar.
Worst week-43.3%Week of 20 Feb.
Latest week+1.0%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains4
Flat weeks0
Modest losses4
Sharp losses10
Recent vol11.9%13-week weekly-return volatility.
Base vol13.8%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew8.5% / -11.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape18/100

Trend, activity pressure, participation, and risk combine to a 18/100 tape read.

 Indicator analysis33/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.20; No reversal markers Next-Week ExpectancyNegative 43.81%

Next-week expectancy is negative with a 43.81% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors49/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment55/100

Weighted news tone is neutral across 56 relevant articles.

Moleculin Biotech Inc (MBRX) Valuation: PE, PB & Fair Value Analysis Insiders6 / 12

6 acquisitions and 12 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.12 USD1.0%2.85 USD73.87 USD0.90-69.67258.2KOff
17 Jul 20262.10 USD-7.9%2.90 USD75.44 USD1.12-71.61614.6KOff
10 Jul 20262.28 USD-13.6%2.96 USD77.03 USD1.31-72.111.1MOff
3 Jul 20262.64 USD-19.3%3.05 USD78.53 USD1.43-68.305.8MOff
26 Jun 20263.27 USD13.5%3.21 USD79.88 USD1.45-61.1414.5MOff
19 Jun 20262.88 USD9.1%3.32 USD81.25 USD1.44-67.82973.5KOff
12 Jun 20262.64 USD10.0%3.58 USD82.53 USD1.34-70.13862.2KOff
5 Jun 20262.40 USD-14.0%3.86 USD83.88 USD1.24-73.351.5MOff
29 May 20262.79 USD16.7%4.18 USD85.31 USD1.10-71.621.4MOff
22 May 20262.39 USD13.3%4.48 USD86.76 USD0.91-76.301.0MOff
15 May 20262.11 USD-14.6%4.80 USD88.13 USD0.90-80.011.9MOff
8 May 20262.47 USD-1.6%5.16 USD89.63 USD0.87-77.88937.5KOff
1 May 20262.51 USD-1.2%5.47 USD91.22 USD0.88-77.67416.1KOff
24 Apr 20262.54 USD5.0%5.77 USD93.12 USD0.91-78.28880.8KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.